Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
5/8 12:45
COPENHAGEN, Denmark; August 5, 2022 Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors Expanded collaboration leverages Genmab’s proprietary HexaBody ® technology platform to develop novel monospecific antibodies First monospecific...